Journal
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
Volume 38, Issue 6, Pages 724-732Publisher
AMER THORACIC SOC
DOI: 10.1165/rcmb.2007-0354OC
Keywords
gene expression profiling; transcriptomics; acute respiratory distress syndrome; elafin; lung disease
Funding
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060710] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER
- NHLBI NIH HHS [HL60710] Funding Source: Medline
- NIEHS NIH HHS [ES00002] Funding Source: Medline
Ask authors/readers for more resources
Previous microarray-based studies of acute respiratory distress syndrome (ARDS) were performed using various models to mimic disease pathogenesis. The complexity of the pathophysiologic response to direct or indirect lung injury in ARDS is difficult to reconstruct in experimental conditions. Thus, direct analysis of ARDS patient blood may provide valuable information. We investigated genome-wide gene expression profiles in paired whole blood samples from patients with ARDS (n = 8) during the acute stage (within 3 d of diagnosis) and recovery stage of ARDS (around ICU discharge). Among 126 differentially expressed genes, peptidase inhibitor 3 (P13, encoding elafin, a potent neutrophil elastase inhibitor) had the largest fold-change (-3-fold changes, acute stage/recovery stage) in expression, indicating down-regulation during the acute stage of ARDS. We further examined plasma P13 levels in 40 patients with ARDS and 23 at-risk control subjects from the same cohort. There was a coincidence of the microarray findings of lower P13 gene expression with the lower plasma P13 during the acute-stage. The plasma P13 levels were statistically significant different among pre-diagnosis, day of diagnosis, and post-diagnosis groups (ANOVA, P = 0.001), with a trend of decreasing from pre- to post-diagnosis group. The time course of plasma P13 decrease is well correlated with the course of early ARDS development (Pearson correlation coefficient: -0.52, P = 0.0006). Considering that P13 can covalently binding to extracellular matrix in lung, circulating P13 may provide a useful clinical marker for monitoring the early development of ARDS and may have implications for ARDS treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available